Impact of new P2Y12 blockers on platelet reactivity and clinical outcomes after acute coronary syndrome: Insight from a large single center registry

IJC Heart and Vessels

Volumn 4, Issue 1, 2014, Pages 188-192

  Deharo, Pierre ^a,b,c   Loosveld, Marie ^a,b,c   Bonnet, Guillaume ^a,b,c   Pankert, Mathieu ^a,b,c   Quilici, Jacques ^a,b,c   Lambert, Marc ^a,b,c   Verdier, Valerie ^d   Morange, Pierre ^a,b,c   Bonnet, Jean Louis ^a,b,c   Alessi, Marie Christine ^a,b,c   Cuisset, Thomas ^a,b,c  

^a TIMONE HOSPITAL   (France)

^b INSERM   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

Author keywords

Acute coronary syndrome; Bleeding; P2Y12 inhibitor; Stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; TICAGRELOR; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; BLEEDING TENDENCY; CONTROLLED STUDY; CORONARY STENTING; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; TRANSIENT ISCHEMIC ATTACK;

EID: 84922226231     PISSN: 22147632     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijchv.2014.04.005     Document Type: Article

References (41)

1. Hamm C.W., Bassand J.P., Agewall S., et al. ESC Committee for Practice Guidelines. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011, 32:2999-3054.
2. Steg P.G., James S.K., Atar D., et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012, 33:2569-2619.
3. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), European Association for Percutaneous Cardiovascular Interventions (EAPCI), Wijns W., Kolh P., Danchin N., et al. Guidelines on myocardial revascularization. Eur Heart J 2010, 31:2501-2555.
4. Yusuf S., Zhao F., Mehta S.R., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494-502.
5. O'Gara P.T., Kushner F.G., Ascheim D.D., et al. 2013ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013, 61:e78-e140.
6. Mehta S.R., Yusuf S., Peters R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001, 358:527-533.
7. Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007, 357:2001-2015.
8. Wallentin L., Becker R.C., Budaj A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009, 36:1045-1057.
9. Lotrionte M., Biondi-Zoccai G.G., Agostoni P., et al. Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention. Am J Cardiol 2007, 100:1199-1206.
10. Buonamici P., Marcucci R., Migliorini A., et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007, 49:2312-2317.
11. Matetzky S., Shenkman B., Guetta V., et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004, 109:3171-3175.
12. Cuisset T., Cayla G., Frere C., et al. Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment?. EuroIntervention 2009, 5:325-329.
13. Cuisset T., Grosdidier C., Loundou A.D., et al. Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA Study (Predictor of Bleedings With Antiplatelet Drugs). JACC Cardiovasc Interv 2013, 6:854-863.
14. Cuisset T., Loosveld M., Morange P.E., et al. CYP2C19 *2 and *17 alleles have a significant Impact on platelet response and bleeding risk in patients treated with Prasugrel after acute coronary syndrome. JACC Cardiovasc Interv 2012, 5:1280-1287.
15. Bonello L., Tantry U.S., Marcucci R., et al. for the Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010, 56:919-933.
16. Parodi G., Bellandi B., Venditti F., et al. Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel. Am J Cardiol 2012, 109:214-218.
17. Mehran R., Rao S.V., Bhatt D.L., et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011, 123:2736-2747.
18. Cutlip D.E., Windecker S., Mehran R., et al. Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007, 115:2344-2351.
19. Wiviott S.D., Trenk D., Frelinger A.L., et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007, 116:2923-2932.
20. Husted S., van Giezen J.J. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther 2009, 27:259-274.
21. Cayla G., Cuisset T., Silvain J., et al. Prasugrel monitoring and bleeding in real world patients. Am J Cardiol 2013, 111:38-44.
22. Geisler T., Zürn C., Simonenko R., et al. Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions. Eur Heart J 2010, 31:59-66.
23. Price M.J., Berger P.B., Teirstein P.S., et al. GRAVITAS Investigators. Standard- vs. high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011, 16(305):1097-1105.
24. Aradi D., Komócsi A., Vorobcsuk A., et al. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am Heart J 2010, 160:543-551.
25. Stone G.W., Witzenbichler B., Weisz G., et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 2013, 382:614-623.
26. Palmerini T., Biondi-Zoccai G., Della Riva D., Mariani A., Genereux P., Branzi A., et al. Stent thrombosis with drug-eluting stents: is the paradigm shifting?. J Am Coll Cardiol 2013, 62:1915-1921.
27. Ben-Dor I., Torguson R., Scheinowitz M., et al. Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents. Am Heart J 2010, 159:871-875.
28. Brar S.S., ten Berg J., Marcucci R., et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol 2011, 58:1945-1954.
29. Campo G., Parrinello G., Ferraresi P., et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 2011, 57:2474-2483.
30. Mangiacapra F., Patti G., Barbato E., et al. A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study. JACC Cardiovasc Interv 2012, 5:281-289.
31. Roy P., Bonello L., Torguson R., et al. Impact of "nuisance" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation. Am J Cardiol 2008, 102:1614-1617.
32. Armero S., Bonello L., Berbis J., et al. Rate of nuisance bleedings and impact on compliance to prasugrel in acute coronary syndromes. Am J Cardiol 2011, 108:1710-1713.
33. Deharo P., Bassez C., Bonnet G., et al. Prasugrel versus Ticagrelor in Acute Coronary Syndrome: a randomized comparison. Int J Cardiol 2014, [in press, letter].
34. Biondi-Zoccai G., Lotrionte M., Agostoni P., et al. Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. Int J Cardiol 2011, 150:325-331.
35. Navarese E.P., Verdoia M., Schaffer A., et al. Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials. QJM 2011, 104:561-569.
36. Steiner S., Moertl D., Chen L., Coyle D., Wells G.A. Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions. Thromb Haemost 2012, 108:318-327.
37. Collet J.P., Cuisset T., Rangé G., et al. ARCTIC Investigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012, 367:2100-2109.
38. Trenk D., Stone G.W., Gawaz M., et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol 2012, 59:2159-2164.
39. Angiolillo D.J., Saucedo J.F., Deraad R., et al. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (Switching Anti Platelet) study. J Am Coll Cardiol 2010, 56:1017e1023.
40. Bernlochner I., Mayer K., Morath T., et al. Antiplatelet efficacy of prasugrel in patients with high on-clopidogrel treatment platelet reactivity and a history of coronary stenting. Thromb Haemost 2013, 109:517-524.
41. Deharo P., Pons C., Pankert M., et al. Effectiveness of switching 'hyper responders' from Prasugrel to Clopidogrel after acute coronary syndrome: The POBA (Predictor of Bleeding with Antiplatelet drugs) SWITCH study. Int J Cardiol 2013, [S0167-527301332-6, letter].